Ovid Q2 FY26 net loss widens to $15 million; operating expenses rise to $16.4 million
Reuters2026/08/13 12:31- Ovid posted a net loss of $15 million, or $0.08 per share, for the quarter ended June 30, 2026.
- Research and development expense rose to $10 million from $6.5 million a year earlier on higher OV329 and OV4071 activity.
- General and administrative expense increased to $6.5 million from $4.9 million; total operating expenses climbed to $16.4 million from $11.3 million.
- Cash, cash equivalents and marketable securities totaled $169.8 million, with runway expected into 2029.
- OV4071 advanced in Phase 1; OV329 began Phase 2 in treatment-resistant focal onset seizures, with photosensitivity results expected near year-end 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"Expensive Protection" Arbitrage Opportunities in a Calm US Stock Market: SocGen Recommends Selling Short-Term Tail Volatility, but Hedging Against Crash Risks
Société Générale stated that the surge in short-term S&P 500 option premiums is creating attractive opportunities for selling volatility strategies, but it is necessary to hedge against downside risk.
BUUU Group signs deal to buy 60% stake in modular data center provider Brightray Science
Goldman Sachs remains bullish on the South Korean stock market: Driven by the AI memory boom, with a potential upside of up to 80%.
Goldman Sachs strategist Timothy Moe maintains his bullish target on the South Korean stock market, believing that investors are underestimating how long the benefits of artificial intelligence (AI) will last for the country's memory chip manufacturers.
Crypto prices
More
